Merck & Co., Inc. MRK secured a favorable recommendation from a European regulatory committee for its cancer therapy Keytruda in combination with Padcev to treat adults facing resectable ...

Merck & Co Inc (NYSE:MRK) recently announced a total dividend of $0.85 per share, with the ex-dividend date set for 2026-09-15. This amount includes a $0.85 per share cash dividend payable on ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Auxier Asset Management, an investment advisory firm, released its second-quarter 2026 investor letter. The letter can be ...

Merck Announce Clinical Collaboration and Supply Agreement to Evaluate [212Pb]PSV359 in Combination with Keytruda (Pembrolizumab) in FAP-a Positive Solid Tumors CI Sep. 14 Perspective Therapeutics ...

Merck launches Your Hive of Whole Health at USCHA 2026, expanding HIV support across physical, mental, emotional and social well-being needs and care.

Drug major Merck & Co., Inc. ( MRK) announced Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending approval of ...

Merck & Co., Inc. (NYSE: MRK) has had a fantastic six months, seeing its share price go up nearly 50%. The company has a valuable portfolio of assets that will enable strong shareholder returns, ...

Merck & Co. stock is supported by DBS’s Buy rating with a USD 180.00 price target as of September 12, 2026. The company ...

Merck & Co. Inc. (NYSE:MRK) agreed on Wednesday to acquire Verona Pharma plc (NASDAQ:VRNA) for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. Each ...

RBC Capital analyst Trung Huynh maintained a Hold rating on Merck & Company yesterday and set a price target of $150.00. Huynh covers the Healthcare sector, focusing on stocks such as Bristol-Myers ...